



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/650,434
(Use several sheets if necessary)				Filing Date	August 28, 2003
				First Name Inventor	Binggeli
				Group Art Unit	
				Examiner Name	
Sheet	12	Of	2	Attorney Docket Number	21377 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
FTP	C1	Keller and Wahli: Trends Endocrin. Metab. (1993); 4:291-296	
↑	C2	MacDougald and Lane: Current Biology Vol. 5 pp. 618-621 (1995)	
	C3	Guerre-Millo, et. al.; J Biol Chem 2000; 275: 16638-16642	
	C4	Balfour, et. al.; Drugs 57 (1999) 921-930	
	C5	Haigh et. al., Tetrahedron: Asymmetry, 10, pp. 1353-1367	
	C6	Gotteland et al., Synlett, 9 pp. 931-932 (1995)	
	C7	Hulin et al., J. Med. Chem., 39, pp. 3897-3907 (1996)	
	C8	Nicolaou et al., J. Am. Chem. Soc., 122, pp. 3830-3838 (2000)	
	C9	Nichols et al., Anal. Biochem., 257, pp. 112-119 (1998)	
	C10	Einsiedel et. al., Bioorg. Med. Chem. Lett., 10, pp. 2041-2044 (2000)	
	C11	Goto et al., Chem. Pharm. Bull., 19, pp. 2050-2057 (1971)	
	C12	Reichstein et al., Helvetica Chimica Acta, 16, pp. 121-129 (1933)	
	C13	Diels et al., chem.. Ber., 48, pp. 897-905 (1915)	
	C14	Wightman et al., J. Org. chem., 43, pp. 2167-2170 (1978)	
	C15	Musser et al., J. Med. Chem. 30, pp. 62-67 (1987)	
	C16	Rahman et al., J. Chem. Soc. Perkin Trans. 1, 12, pp. 2973-2977 (1983)	
	C17	Kelly et. al., J. Am. Chem. Soc., 110, pp. 6471-6480 (1988)	
	C18	Kneen et al., Synthetic Communications, 16, pp. 1635-1640 (1986)	
	C19	Kim et al., Can. J. Chem., 60, pp. 2093-2098 (1982)	
	C20	Pàrkànyi et al., Monatsh. Chem., 123, pp. 637-645 (1992)	
	C21	STN International ® CAPLUS Database, Accession No. 2000; 117035; Collins et al., WO 2000008002, abstract	
	C22	Malamas, MS et al, Eur. J. Med. Chem. Vol . 36, No. 1 (2001) pp. 31-42	
	C23	Hulin, B. et al., Current Pharmaceutical Design, Vol.2 (1996) pp. 85-102	
FTP	C24	Oplinger, et. al., ACS National Meeting, San Diego, April 1-5, 2001, Poster 238, Division of Medicinal Chemistry, Section C	
Examiner Signature	Fiona T. Powers		DATE CONSIDERED 4/30/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.

O I P E
J C 103
DEC 8 2003
TELE & TRADEMAK CERT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known			
				Application Number	10/650,434		
				Filing Date	August 28, 2003		
				First Name Inventor	Binggeli		
				Group Art Unit			
				Examiner Name			
Sheet	1	of	2	Attorney Docket Number	21377 US		
U.S. PATENT DOCUMENTS							
Examiner Initials'	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
FTP	A1	5,856,529		Bristol-Myers Squibb Company Catt et al.	01/05/1999		
↑	A2	6,121,397		Xerox Corporation MacLeod et al.	09/19/2000		
	A3	5,089,514		Bernard Hulin	02/18/1992		
	A4	4,011,326		Jensen	03/08/1977		
	A5	6,291,685		Junghans, et. al.	09/18/2001		
↓	A6	6,441,185		Kühnle, et. al.	08/27/2002		
FTP	A7	5,599,826		Mertens, et. al.	02/04/1997		
FOREIGN PATENT DOCUMENTS							
Examiner Initials'	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
FTP	B1	EP 1 078 923		F. Hoffmann-La Roche A.G.	02/28/2001		
↑	B2	WO 99/10339		Pfizer Products Inc.	03/04/1999		
	B3	WO 02 16331		Eli Lilly & Company	02/28/2002		
	B4	WO 00 08002		Glaxo Group Limited	02/17/2000	X	
	B5	WO 91/19702		Pfizer Inc.	12/26/1991		
	B6	WO 94/01420		Smithkline Beecham PLC.	01/20/1994		
	B7	WO 94/13650		Smithkline Beecham PLC.	06/23/1994		
	B8	WO 95/17394		Smithkline Beecham PLC	06/29/1995		
	B9	WO 97/25042		Smithkline Beecham PLC	07/17/1997		
↓	B10	WO 99/08501		Dr. Reddy's Research Foundation	02/25/1999		
FTP	B11	EP 0903343		SSP Co., Ltd.	03/24/1999		
Examiner Signature	↑	Date Considered	4/30/04				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

Fiona T. Powers